Repligen Corporation (RGEN) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Repligen Corporation (RGEN:NASDAQ), powered by AI.

Current Price
$131.69
P/E Ratio
151.5
Market Cap
7.4B
Sector
Healthcare
What is the Repligen Corporation stock price forecast?

Repligen Corporation is currently trading at $131.69. View real-time AI analysis on Alpha Lenz.

What is Repligen Corporation insider trading activity?

View the latest insider trading data for Repligen Corporation on Alpha Lenz.

What is Repligen Corporation's P/E ratio?

Repligen Corporation's P/E ratio is 151.5.

Repligen Corporation

NASDAQ · RGEN
$131.69+0.82(+0.63%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about Repligen Corporation's future dividend policy...
Alpha Chat Insight

Repligen Corporation trades at a P/E of 151.5 (premium valuation) with modest ROE of 2.4%.

Ask for details

Company Overview

Repligen Corporation is a leading global provider of bioprocessing technologies and solutions that support the development and manufacture of biologic drugs. Specializing in high-value consumable products, Repligen plays a pivotal role in the biotechnology and pharmaceutical sectors by supplying sophisticated products such as Protein A affinity ligands, advanced filtration systems, and ready-to-use chromatography columns—essential tools for the purification and production of complex biologics, including monoclonal antibodies. The company’s innovative portfolio serves major life sciences firms and contract manufacturing organizations worldwide, helping to increase efficiency, reliability, and yield in drug production processes. Headquartered in Waltham, Massachusetts, Repligen Corporation maintains a strong manufacturing footprint in Europe, underscoring its global reach and commitment to supporting the rapidly expanding biopharmaceutical market. With over 1,700 employees and continuous investment in research and development, Repligen is recognized for driving advancements in bioprocessing that are critical to meeting the growing demand for biologic therapies. Its contributions are integral to the lifecycle of next-generation medicines, making it a key enabler for both established and emerging biopharma companies.

CEOMr. Olivier Loeillot
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees1,778

Company Statistics

FY 2025

Profile

$7.41BMarket Cap
$738.26MRevenue
0.00Shares Out
1,778Employees

Margins

52.32%Gross
18.92%EBITDA
5.63%Operating
8.45%Pre-Tax
6.62%Net

Valuation

151.46P/E
3.52P/B
10.03EV/Sales
53.91EV/EBITDA
80.77P/FCF

Growth (CAGR)

-2.70%Rev 3Yr
15.05%Rev 5Yr
-40.36%Op Inc 3Yr
-9.86%Op Inc 5Yr
-35.94%Net Inc 3Yr
-3.99%Net Inc 5Yr

Returns

1.69%ROA
2.40%ROE
2.90%ROIC

Financial Health

$566.02MCash & Cash Equivalents
$277.55MNet Debt
40.05%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Repligen Corporation (ticker: RGEN) is a company listed on NASDAQ in the Healthcare sector (Medical Instruments & Supplies). It has approximately 1,778 employees. Market cap is $7.4B.

The current price is $131.69 with a P/E ratio of 151.46x and P/B of 3.52x.

ROE is 2.40% and operating margin is 5.63%. Annual revenue is $738M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Repligen Corporation (RGEN) Stock Forecast 2026 $131.69 — Price, Financials & Analyst Targets | Alpha Lenz